Eye and eyelid abnormalities are common in patients with hashimoto's thyroiditis

Thyroid

Volumn 20, Issue 3, 2010, Pages 287-290

  Tjiang, Hilman ^a   Lahooti, Hooshang ^a   McCorquodale, Tom ^a   Parmar, Kishan R ^a   Wall, Jack R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

THYROTROPIN RECEPTOR ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; AUSTRALIA; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; EYELID DISEASE; EYELID MUSCLE; EYELID RETRACTION; FEMALE; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UPPER EYELID RETRACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CALSEQUESTRIN; COLLAGEN TYPE XIII; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE; EYE DISEASES; EYELIDS; FEMALE; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 77649320580     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0199     Document Type: Article

References (31)

1. Brownlie BE, Newton OA, Singh SP 1975 Ophthalmopathy associated with primary hypothyroidism. Acta Endocrinol 79:691-699.
2. Grzesiuk W, Szydlarska D, Pragacz A, Bar-Andziak E 2008 Thyroid-associated orbitopathy in patients with Hashimoto's thyroiditis. Pol Arch Med Wewn 118:318-321.
3. Yamada M, Li AW, Wall JR 2000 Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management. Crit Rev Clin Lab Sci 37:523-549.
4. Burch HB, Wartofsky L 1993 Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14:747-793.
5. Tamagno G, De Carlo E, Betterle C, Murialdo G 2004 Graves' ophthalmopathy and atrophic thyroiditis: a case report. J Endocrinol Invest 27:163-166.
6. Weetman AP 2000 Graves' disease. N Engl J Med 343: 1236-1248.
7. Wall JR, Salvi M, Bernard NF, Boucher A, Haegert D 1991 Thyroid-associated ophthalmopathy - a model for the association of organ-specific autoimmune disorders. Immunol Today 12:150-153.
8. El-Kaissi S, Frauman A, Wall J 2004 Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J 34:482-491.
9. Weetman AP 1997 Eyeing up Graves' ophthalmopathy. Mol Cell Endocrinol 126:113-116.
10. Bahn RS 2003 Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 88:1939-1946.
11. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE 1998 Thyrotropin receptor expression in Graves' orbital adipose=connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 83:998-1002.
12. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M 2003 Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 30:369-380.
13. Beard NA, Laver DR, Dulhunty AF 2004 Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Biophys Mol Biol 85:33-69.
14. Tani J, Wall JR 2006 Analysis - can the development of thyroid-associated ophthalmopathy be explained by autoimmunity against eye muscle antigens? Can Med Assoc J 17:239-241.
15. Gopinath B, Musselman R, Beard N, Tani J, Adams C, Wall JR 2006 Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are sensitive and specific markers of ocular myopathy in patients with Graves' disease. Clin Exp Immunol 145:56-62.
16. Hagg P, Rehn M, Huhtala P, Vaisanen T, Tamminen M, Pihlajaniemi T 1998 Type XIII collagen is identified as a plasma membrane protein. J Biol Chem 273:15590-15597.
17. Gopinath B, Musselman R, Adams C, Tani J, Beard N, Wall JR 2006 Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy - correlation with clinical features. Thyroid 16:967-974.
18. De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall JR, Bellastella A, Bizzarro A 2005 Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy. Clin Endocrinol (Oxf) 62:24-29.
19. Nunery WR, Martin RT, Heinz GW, Gavin TJ 1993 The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg 9:77-83.
20. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L 1997 Clinical activity score as a guide in the management of patients with Graves' Ophthalmopathy. Clin Endocrinol (Oxf). 47:9-14.
21. Werner SC 1969 Classification of the eye changes of Graves' disease. Am J Ophthalmol 68:646-648.
22. Gopinath B, Adams CL, Musselman R, Tani J, Wall JR 2007 Antibodies against calsequestrin and type XIII collagen are good markers for chronic upper eyelid lag and retraction. Ocul Immunol Inflamm 15:81-88.
23. Gopinath B, Tani J, Bao N, Wall JR 2007 Eye muscle and collagen XIII antibodies and eye signs in patients with transient and chronic thyroiditis. Thyroid 17:1-7.
24. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA 1996 Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284-290.
25. Bartley GB, Gorman CA 1995 Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol 119:792-795.
26. Grove AS 1981 Upper eyelid retraction and Graves' disease. Ophthalmology 88:499-506.
27. Nassar MM, Dickinson AJ, Neoh C, Powell C, Buck D, Galal E, Clarke MP 2009 Parameters predicting outcomes of strabismus surgery in the management of Graves' ophthalmopathy. J AAPOS 13:236-240.
28. Bartalena L, Tanda ML 2009 Clinical practice. Graves' ophthalmopathy. N Engl J Med 360:994-1001.
29. Lim SL, Lim AK, Mumtaz M, Hussein E, Wan Bebakar WM, Khir AS 2008 Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves' disease. Thyroid 18:1297-1301.
30. Salvi M, Scalise D, Stolarski C, Arthurs B, Lindley S, Kennerdell J, Wall JR 1995 Upper eyelid retraction in the absence of other evidence for progressive ophthalmopathy is associated with eye muscle autoantibodies. Clin Immunol Immunopathol 74:44-50.
31. Miller A, Arthurs B, Boucher A, Liberman A, Bernard N, Salvi M, Wall JR 1992 Significance of antibodies reactive with a 64-kDa eye muscle membrane antigen in patients with thyroid autoimmunity. Thyroid 2:197-202.